Using methods that allow for the dissection of mode of action and indication of target disease simultaneously can offer an ideal and efficient approach to drug discovery. In the area of inflammations where compounds may have the possibility of acting upon the adaptive immune response, the Senerga® Mode of Action platform enables the tracking of the key events that are common to all adaptive immune responses. This provides a great advantage to compounds that are in intial phases of discovery or those compounds which are slated for repositioning.
Download the whitepaper to learn more:
- Technology behind the Senerga® Mode of Action platform
- Customizations for individual programs
- Experimental methods
- Proof of concept for FTY720